USIS Washington File - July 31, 2006

University of California Davis (UC Davis) researchers conducted the study with support from the National Institutes of Health (NIH). The findings are reported in the August edition of the Journal of Virology.

In a three year study of patients living with HIV/AIDS, the researchers found that the virus is able to survive efforts to destroy it by hiding in the mucous tissues that line the intestine, continuing to suppress the patient's immune system, even while a regimen of drug treatment may be under way.

"The real battle between the virus and exposed individuals is happening in the gut immediately after viral infection," said Satya Dandekar, senior author of the study and the chair of the Department of Medical Microbiology at UC Davis. "We need to be focusing our efforts on improving treatment of gut mucosa [the mucous membrane lining the alimentary canal from mouth to anus] where massive destruction of immune cells is occurring."

Previous research has shown that lymphoid tissue makes a significant contribution to the body's immune response and its capability to combat the HIV virus. Dandekar said these new findings underscore the importance of finding ways to protect the function of lymphoid tissue.

The findings reported in the Journal of Virology showed inflammation in the gut disrupted tissue function, and promoted cell death. The researchers suggest that the prevention of inflammation is one key to preserving the immune response in the gut. Anti-inflammatory drugs may help, the researchers suggest, and could improve the effectiveness of HAART treatment.

Early initiation of highly active anti-retroviral therapy - HAART - was another factor that appeared to prevent inflammation and better enable the gut mucosal immune system to do its job. HIV-positive persons who had begun drug treatment within weeks of their initial exposure to the virus had much better outcomes than those who were known to be infected for more than one year.

"What we continue to see is that restoration of immune function is more likely when treatment is started early," said gastroenterologist Thomas Prindiville, a co-author of the study. "If you are able to restore the gut's immune response, the patient will be more likely to clear the virus."

DISEASE-FIGHTING PROTEINS

A second study released in the new medical literature finds that some of the answers to beating HIV/AIDS may be found in the body's own systems.

Earlier in 2006, researchers at the Indiana University School of Medicine-Northwest identified a protein produced by the body itself that serves as a first line of defense against bacterial infections.

In the July 28 issue of the Journal of Biological Chemistry, Roman Dziarsky and Dipika Gupta, propose that these proteins called PGLYRP - for peptidoglycan recognition proteins - might be used to develop medications that could boost the impaired day-to-day response to bacteria of the HIV-infected person. It is a strategy that could help persons living with HIV/AIDS, the researchers suggest, but also people suffering from other maladies, which cripple the immune system.

Many parts of the body produce these bacteria-fighting proteins, the Indiana University researchers report. In healthy people, these proteins mount a defense and easily prevent bacterial infections. PGLYRP also appear to be the system's "first responders" at the introduction of infection, moving into action before the main immune system responds.

For information on U.S. policy, see HIV/AIDS.

(Distributed by the Bureau of International Information Programs, U.S. Department of State. Web site: http://usinfo.state.gov)

060731
US060705

Copyright © 2006 - US Information Agency. Reproduction of this article (other than one copy for personal reference) must be cleared through the USIA.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .